Equities Analysts Issue Forecasts for Bruker FY2024 Earnings

Bruker Co. (NASDAQ:BRKR) – Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Bruker in a report released on Monday, December 23rd. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.39 per share for the year, down from their previous forecast of $2.40. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.52 EPS, Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.71 EPS, FY2025 earnings at $2.76 EPS, Q3 2026 earnings at $0.81 EPS and FY2026 earnings at $3.41 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.74 EPS.

BRKR has been the subject of a number of other reports. Guggenheim began coverage on Bruker in a research note on Thursday, December 19th. They set a “buy” rating and a $72.00 target price for the company. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Barclays decreased their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Citigroup cut their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $74.45.

Bruker Trading Up 1.5 %

NASDAQ BRKR opened at $58.25 on Wednesday. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The firm has a 50-day moving average price of $57.73 and a 200 day moving average price of $62.30. The stock has a market capitalization of $8.83 billion, a P/E ratio of 28.00, a P/E/G ratio of 4.00 and a beta of 1.18. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s payout ratio is currently 9.62%.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently modified their holdings of the company. True Wealth Design LLC raised its position in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares during the last quarter. UMB Bank n.a. grew its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker in the 2nd quarter valued at $52,000. GAMMA Investing LLC lifted its stake in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after purchasing an additional 388 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in Bruker in the 3rd quarter worth about $73,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.